Wedge Capital Management L L P NC Sells 30,981 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Wedge Capital Management L L P NC trimmed its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 10.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 255,460 shares of the specialty pharmaceutical company’s stock after selling 30,981 shares during the quarter. Wedge Capital Management L L P NC owned 0.45% of Jazz Pharmaceuticals worth $36,418,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System increased its stake in Jazz Pharmaceuticals by 4.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 73,439 shares of the specialty pharmaceutical company’s stock worth $10,498,000 after acquiring an additional 2,974 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in Jazz Pharmaceuticals by 16.8% in the 1st quarter. Envestnet Asset Management Inc. now owns 45,261 shares of the specialty pharmaceutical company’s stock worth $6,470,000 after acquiring an additional 6,496 shares during the last quarter. LSV Asset Management increased its stake in Jazz Pharmaceuticals by 31.0% in the 1st quarter. LSV Asset Management now owns 1,001,650 shares of the specialty pharmaceutical company’s stock worth $143,185,000 after acquiring an additional 237,190 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Jazz Pharmaceuticals by 16.5% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 111,430 shares of the specialty pharmaceutical company’s stock worth $15,929,000 after acquiring an additional 15,821 shares during the last quarter. Finally, Redmile Group LLC increased its stake in Jazz Pharmaceuticals by 97.2% in the 1st quarter. Redmile Group LLC now owns 269,480 shares of the specialty pharmaceutical company’s stock worth $38,522,000 after acquiring an additional 132,800 shares during the last quarter. Institutional investors own 89.59% of the company’s stock.

In other news, Director Catherine A. Sohn sold 726 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $135.65, for a total value of $98,481.90. Following the sale, the director now directly owns 9,574 shares of the company’s stock, valued at $1,298,713.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.30% of the company’s stock.

NASDAQ:JAZZ traded down $3.14 on Wednesday, reaching $133.53. 91,151 shares of the company’s stock traded hands, compared to its average volume of 572,309. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.52 and a current ratio of 3.71. The stock’s 50-day moving average is $138.42. The stock has a market capitalization of $7.75 billion, a price-to-earnings ratio of 10.91, a PEG ratio of 1.14 and a beta of 1.14. Jazz Pharmaceuticals PLC has a 12 month low of $113.52 and a 12 month high of $177.48.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 EPS for the quarter, beating the Zacks’ consensus estimate of $3.16 by $0.49. The business had revenue of $534.13 million for the quarter, compared to analysts’ expectations of $507.23 million. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the firm earned $3.49 earnings per share. As a group, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 13.33 EPS for the current year.

A number of research firms have recently issued reports on JAZZ. Royal Bank of Canada set a $184.00 price objective on Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, July 3rd. ValuEngine upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 8th. Barclays upped their price objective on Jazz Pharmaceuticals from $164.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Mizuho set a $148.00 price objective on Jazz Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, July 3rd. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Monday, June 17th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $176.53.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: How are the companies in the S&P 500 selected?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply